Navigation Links
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
Date:10/1/2007

ectable virus 24 weeks after stopping therapy, which clevudine previously demonstrated in Bukwang's South Korean registration studies.

At week 72, HBeAg- patients in Study 306 who have been treated with clevudine and have suppressed HBV DNA and normalized ALT levels will be randomized to continue active clevudine or switch to placebo. The purpose is to determine the proportion of patients who sustain a virologic response 24 weeks after stopping clevudine treatment at week 96. HBeAg+ patients in Study 305 that have been treated with either clevudine or Hepsera and undergo eAg seroconversion (loss of eAg with suppressed HBV DNA and normalized ALT) will discontinue therapy at week 72. SVR will be assessed in these HBeAg+ patients for clevudine and Hepsera 24 weeks after stopping treatment at week 96.

South Korean Registration Studies for Clevudine

Bukwang received marketing approval for clevudine from the South Korean FDA based on two 24-week, randomized (3:1), double-blind, placebo-controlled, multi-center South Korean Phase 3 registration trials in 337 patients. Study 301 enrolled 248 HBeAg+ patients who received clevudine 30 mg or a placebo once-daily, and Study 302 enrolled 89 HBeAg- patients who received clevudine 30 mg or a placebo once-daily. All patients were evaluated for an additional 24 weeks of follow-up care without clevudine treatment.

After 24 weeks of clevudine treatment, 59% of HBeAg+ patients achieved undetectable HBV DNA (<300 copies/mL) and 92% of HBeAg- patients achieved undetectable HBV DNA. These results were statistically significant compared to placebo. In addition to the potent antiviral suppression, 16% of the HBeAg- patients who received clevudine demonstrated a sustained virologic response (SVR) 24 weeks after stopping therapy, versus 0% of the patients who had received the placebo. In Study 303, a South Korean open-label, follow-on study of clevudine, Bukwang observed similar findings to those noted above for Studie
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. , Sept. 19, ... (PGDx), a provider of advanced cancer genome analysis ... a leader in discovering and developing highly selective ... the first-ever comprehensive genomic study of malignant mixed ... of the female reproductive system, also known as ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Medical, Inc., the wholly-owned operating subsidiary of Patient ... the recently released 2011-2012 U.S. News and World ... of the SurgiCount Safety-Sponge® System, a clinically proven ... common surgical errors, retained surgical sponges.  Only 17 ...
... A new policy recommendation released on 20 July by ... of serological (blood) tests to diagnose active tuberculosis (TB). ... are different to QuantiFERON, which measures responses of white ... Active tuberculosis occurs when the TB organism has overcome ...
Cached Medicine Technology:SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 2SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 2Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 4
(Date:9/19/2014)... 19, 2014 “Copay coupons,” a drug ... brand drugs among patients with prescription drug coverage, may ... a new report from the Department of Health ... Federal anti-kickback laws prohibit suppliers from offering side-payments to ... federal government. , The report highlights that two recent ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 On September ... at the Platinum PR and Top Places to Work ... New York City. Camino received honorable mentions in two ... — for its work elevating Latina voices in the ... organization and be a part of its efforts to ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 According ... manufacturers of the embattled blood-thinner Xarelto, named as defendants ... of Common Pleas, have moved the court to dismiss ... do not have sufficient connection with Philadelphia.* The cases ... et al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Although there ... health benefits, most middle-aged and older adults in ... of exercise, according to new research. Less ... muscle-strengthening recommendations set by the Department of Health ... Strength is essential for promoting health and fitness ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called ... human health. This therapy has grown tremendously across USA in ... effective, safe and dependable. It has far reaching benefits for ... live a very healthy and active lifestyle even beyond their ... a senior therapist at MetroMD said, “HGH or Human Growth ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... declines or local extinctions in a majority of species ... study from the University of Illinois shows that parasites ... species in fragmented forests. This is the first study ... of infectious parasites on animals already stressed by disturbances ...
... the lifestyle habits that children and adolescents develop -- ... fruits and vegetables, being physically inactive or sedentary, and ... a major impact on their health later in life. ... behavior should be taking more of a lead role ...
... Claims Center To, Evaluate Numerous Possible Lawsuits Related to ... Leads Used With Medtronic Implantable Defibrillators, NEW ... were implanted into hundreds of thousands of,people, leaving all of ... fractures. As a result of this, Parker Waichman Alonso LLP ...
... Public Schools in New York, New ... Jersey and Connecticut, ... rate monitors and fitness assessment technology, and a founding,member of the ... provide grant recipients in New York, New,Jersey and Connecticut with heart ...
... Company provides FREE assistance for families seeking ... senior living and nursing homes guidance, SEATTLE, ... service of senior care options, is available for free to ... 2,000 senior housing properties in the state of California and ...
... DC Teen, Miss DC and Miss Maryland Will Also Walk, BETHESDA, Md., Oct. 24 ... International, will lead Marriott employees ... area in this year,s torch relay to raise $1.25 million ... Miss DC Teen, and Miss ...
Cached Medicine News:Health News:Parasites a key to the decline of red colobus monkeys in forest fragments 2Health News:Parasites a key to the decline of red colobus monkeys in forest fragments 3Health News:Child health psychologists need to promote adult disease prevention 2Health News:Medtronic Sprint Fidelis Defibrillator Lead Lawsuit Claims Center Opens to Aid Victims 2Health News:Medtronic Sprint Fidelis Defibrillator Lead Lawsuit Claims Center Opens to Aid Victims 3Health News:Polar Joins Alliance to Combat Childhood Obesity 2Health News:Polar Joins Alliance to Combat Childhood Obesity 3Health News:A Place for Mom Offers Free Assistance to California Seniors Displaced by Wildfires 2Health News:Chairman and CEO Bill Marriott to Lead Marriott Employees in Torch Relay to Raise $1.25 Million for Children's Hospitals Nationwide 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: